Agios Pharmaceuticals (AGIO) Receives “Buy” Rating from Cann
“Agios announced on December 5, 2017 the appointment of Jacqualyn Fouse, Ph.D. to its board of directors. Dr. Fouse has served as executive chair of Dermavant since July 2017 and was previously chief operating officer of Celgene and member of Celgene’s board of directors.”,” the firm’s analyst wrote.
A number of other research analysts also recently commented on the company. SunTrust Banks set a $80.00 target price on Agios Pharmaceuticals and gave the company a buy rating in a research note on Sunday, November 19th. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the company a buy rating in a research note on Friday, November 17th. Credit Suisse Group boosted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. J P Morgan Chase & Co restated a buy rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Finally, Royal Bank Of Canada initiated coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an outperform rating and a $78.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Agios Pharmaceuticals has a consensus rating of Buy and an average price target of $75.70.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. During the same quarter in the previous year, the company posted ($1.63) earnings per share. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. equities research analysts forecast that Agios Pharmaceuticals will post -6.59 EPS for the current fiscal year.
In related news, CEO David P. Schenkein sold 80,000 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $70.14, for a total transaction of $5,611,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David P. Schenkein sold 35,000 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $67.12, for a total value of $2,349,200.00. Following the transaction, the chief executive officer now directly owns 35,000 shares of the company’s stock, valued at approximately $2,349,200. The disclosure for this sale can be found here. Insiders sold 178,908 shares of company stock valued at $12,157,364 in the last ninety days. Insiders own 5.43% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. QS Investors LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth about $144,000. Teacher Retirement System of Texas acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $225,000. S&CO Inc. acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $227,000. Cubist Systematic Strategies LLC lifted its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $245,000. 94.38% of the stock is owned by institutional investors and hedge funds.
WARNING: “Agios Pharmaceuticals (AGIO) Receives “Buy” Rating from Cann” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/06/agios-pharmaceuticals-agio-receives-buy-rating-from-cann.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.